Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
J Am Acad Dermatol. 2012 May;66(5):807-12. doi: 10.1016/j.jaad.2011.12.015. Epub 2012 Jan 13.
Several studies have proven the efficacy of pulsed dye laser (PDL) in the treatment of plaque type psoriasis. However, only two published studies indicate the effectiveness of PDL on nail psoriasis.
We sought to study the effect of different pulse durations in the treatment of nail psoriasis with the 595-nm PDL to determine the optimal pulse duration.
Twenty patients with bilateral fingernail psoriasis were recruited and completed a 6-month trial. PDL was applied on the proximal and lateral nailfolds based on random assignment. Forty nails were treated with 6-millisecond pulse duration and 9 J/cm(2) whereas 39 nails were treated with 0.45-millisecond pulse duration and 6 J/cm(2). Patients were blinded to pulse durations. One blinded dermatologist used the Nail Psoriasis Severity Index (NAPSI) to assess the clinical outcome from pretreatment and posttreatment photographs. Patients were monitored for adverse events. Pain was evaluated after the procedure using a visual analog scale assessed by the patient.
After 6 months of first treatment, there was a significant reduction in overall NAPSI, nail matrix NAPSI, and nail bed NAPSI scores from baseline in both groups; however, no significant difference was found between the two pulse duration groups. Side effects were mild including transient petechiae and hyperpigmentation.
There was no placebo group.
PDL was found to be an effective and well-tolerated option in the treatment of nail psoriasis. No significant difference in terms of efficacy was found between the longer and shorter pulse duration treatment groups.
多项研究已经证实脉冲染料激光(PDL)治疗斑块型银屑病的疗效。然而,仅有两项已发表的研究表明 PDL 对甲银屑病有效。
我们旨在研究不同脉宽的 595nm PDL 治疗甲银屑病的疗效,以确定最佳脉宽。
招募了 20 例双侧甲银屑病患者,并完成了 6 个月的试验。根据随机分配,在近端和侧甲皱襞上应用 PDL。40 个指甲接受 6 毫秒脉宽和 9 J/cm²治疗,39 个指甲接受 0.45 毫秒脉宽和 6 J/cm²治疗。患者对脉宽均不知情。一位盲法皮肤科医生使用甲银屑病严重程度指数(NAPSI)评估治疗前后照片的临床疗效。监测患者的不良反应。患者在治疗后通过视觉模拟评分法(VAS)自行评估疼痛。
首次治疗后 6 个月,两组患者的总体 NAPSI、甲母质 NAPSI 和甲床 NAPSI 评分均较基线显著降低;但两组间无显著差异。不良反应轻微,包括短暂瘀点和色素沉着过度。
无安慰剂组。
PDL 是治疗甲银屑病的一种有效且耐受良好的选择。较长和较短脉宽治疗组在疗效方面无显著差异。